blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4006053

EP4006053 - METHOD FOR TREATING AUTOIMMUNE DISEASE BY IL-17 ANTAGONIST [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  13.12.2024
Database last updated on 08.04.2026
FormerRequest for examination was made
Status updated on  29.04.2022
FormerThe international publication has been made
Status updated on  05.02.2021
Most recent event   Tooltip01.07.2025New entry: Renewal fee paid 
Applicant(s)For all designated states
Jiangsu Hengrui Medicine Co., Ltd.
No. 7 Kunlunshan Road
Economic and Technological Development Zone
Lianyungang, Jiangsu 222047 / CN
For all designated states
Shanghai Hengrui Pharmaceutical Co., Ltd
No.279 Wenjing Road
Economic and Technological Development Zone
Minhang District
Shanghai 200245 / CN
[2022/22]
Inventor(s)01 / SUN, Piaoyang
No.7 Kunlunshan Road, Economic and Technological
Development Zone
Lianyungang, Jiangsu 222047 / CN
02 / ZHANG, Lianshan
No.7 Kunlunshan Road, Economic and Technological
Development Zone
Lianyungang, Jiangsu 222047 / CN
03 / CHEN, Jianwen
No.7 Kunlunshan Road, Economic and Technological
Development Zone
Lianyungang, Jiangsu 222047 / CN
04 / XU, Qian
No.7 Kunlunshan Road, Economic and Technological
Development Zone
Lianyungang, Jiangsu 222047 / CN
05 / GAO, Qunjie
No.7 Kunlunshan Road, Economic and Technological
Development Zone
Lianyungang, Jiangsu 222047 / CN
 [2022/22]
Representative(s)dompatent
Partnerschaft von
Patentanwälten und Rechtsanwälten mbB
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln / DE
[N/P]
Former [2022/22]dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln / DE
Application number, filing date20845895.029.07.2020
[2022/22]
WO2020CN105510
Priority number, dateCN20191069526130.07.2019         Original published format: CN201910695261
CN20201052339310.06.2020         Original published format: CN202010523393
[2022/22]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021018191
Date:04.02.2021
Language:ZH
[2021/05]
Type: A1 Application with search report 
No.:EP4006053
Date:01.06.2022
Language:EN
[2022/22]
Search report(s)International search report - published on:CN04.02.2021
(Supplementary) European search report - dispatched on:EP23.09.2022
ClassificationIPC:C07K16/24, C12N15/13, A61K39/395, A61P37/02, A61P19/02
[2022/22]
CPC:
C07K16/244 (EP,US); A61K39/3955 (US); A61P19/02 (EP,US);
A61P37/02 (EP,US); A61K2039/505 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/22]
TitleGerman:VERFAHREN ZUR BEHANDLUNG EINER AUTOIMMUNKRANKHEIT DURCH IL-17-ANTAGONISTEN[2022/22]
English:METHOD FOR TREATING AUTOIMMUNE DISEASE BY IL-17 ANTAGONIST[2022/22]
French:MÉTHODE DE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE PAR UN ANTAGONISTE DE L'IL-17[2022/22]
Entry into regional phase24.02.2022Translation filed 
24.02.2022National basic fee paid 
24.02.2022Search fee paid 
24.02.2022Designation fee(s) paid 
24.02.2022Examination fee paid 
Examination procedure24.02.2022Examination requested  [2022/22]
21.04.2023Amendment by applicant (claims and/or description)
21.04.2023Date on which the examining division has become responsible
12.12.2024Despatch of a communication from the examining division (Time limit: M04)
10.04.2025Reply to a communication from the examining division
Fees paidRenewal fee
27.07.2022Renewal fee patent year 03
23.06.2023Renewal fee patent year 04
01.07.2024Renewal fee patent year 05
30.06.2025Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[IY] EP3072905  (SHANGHAI HENGRUI PHARM CO LTD et al.) [I] 1-15 * example 6; claims 1-32 *[Y] 4-6,8
 [XY]   GLATT SOPHIE: "Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation", 23 December 2017 (2017-12-23), pages 523 - 532, XP055960145, Retrieved from the Internet [retrieved on 20220912] [X] 1-3,7,9-11,13-15 * abstract * [Y] 4-6,8
 [XY]   SILFVAST-KAISER ANNIKA ET AL: "Anti-IL17 therapies for psoriasis", vol. 19, no. 1, 31 December 2018 (2018-12-31), pages 45 - 54, XP009539080, ISSN: 1744-7682, Retrieved from the Internet [retrieved on 20181208], DOI: 10.1080/14712598.2019.1555235 [X] 1-3,9,11-15 * abstract; figure 1 * * page 47, column r, paragraph 2 * * page 48, column l, paragraph last - page 49, column r, paragraph 1 * [Y] 4-6,8

DOI:   http://dx.doi.org/10.1080/14712598.2019.1555235
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.